# Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

> **NCT00991211** · PHASE3 · COMPLETED · sponsor: **University of Giessen** · enrollment: 549 (actual)

## Conditions studied

- Non-Hodgkin Lymphomas
- Follicular Lymphomas
- Immunocytomas
- Lymphocytic Lymphomas
- Marginal Zone Lymphomas

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Standard chemotherapy CHOP + Ritiximab

## Key facts

- **NCT ID:** NCT00991211
- **Lead sponsor:** University of Giessen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991211, "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00991211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*